Mylan to cut 100 in Puerto Rico

Workers in Caguas, Puerto Rico, braced for the axe as Mylan announced it would eliminate 100 of the 500 positions at that manufacturing plant. The generics maker announced back in March that it would embark on a big restructuring plan to cut costs, eliminating some jobs in the process, but this the first tangible evidence of that plan in motion. In cutting back on the manufacturing side, Mylan joins a host of other drugmakers, some of which have shuttered entire plants as they streamline operations and outsource more operations. In Puerto Rico alone, pharma has sliced some 3,000 jobs.

- read the Associated Press story
- see the Pharmalot post

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.